Risankizumab, an IL23 inhibitor, for ankylosing spondylitis results of a randomised, doubleblind, placebocontrolled, proofofconcept, dosefinding phase 2 study Dominique Baeten Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
